Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07772960
PHASE1
Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes
Sponsor: Yale University
View on ClinicalTrials.gov
Summary
This study will examine two doses of 1.0 mg and 2.0 mg of Semaglutide versus placebo in patients with Alcohol Use Disorder (AUD) and Obesity (Ob) to assess if these doses improve alcohol craving, stress and alcohol use outcomes.
Key Details
Gender
All
Age Range
18 Years - 68 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2026-10-01
Completion Date
2031-10-31
Last Updated
2026-08-19
Healthy Volunteers
No
Interventions
OTHER
Placebo
Placebo - administered one weekly for 20 weeks
DRUG
Semaglutide 1.0 mg
Semaglutide 1.0 mg low dose
DRUG
Semaglutide 2.0 mg
Semaglutide 2.0 mg high dose
Locations (1)
Yale Stress Center
New Haven, Connecticut, United States